Published in:
01-12-2009 | Erratum
Meta-Analysis of Randomized and Controlled Treatment Trials for Achalasia
Published in: Digestive Diseases and Sciences | Issue 12/2009
Login to get accessExcerpt
The article was published with several citation errors in Table 1. The corrected Table 1 appears below.
Table 1
Characteristics of 16 studies included in our meta-analysis of different treatment methods for achalasia
|
The mode of comparison
|
Reference
|
Sample size, mode of treatment
|
Age, mean (range), year
|
Sex (% male)
|
Duration of symptoms, mean (range), month
|
Symptom scores
|
Median follow-up mean (range), month
|
|
|---|---|---|---|---|---|---|---|---|
|
Before
|
After
|
|||||||
|
Non-sugery methods: differences treatment methods compared with pneumatic dilation
|
||||||||
|
Coccia et al. [14]
|
16 PD
14 nifedipine
|
49.5 (18–82)
51 (17–83)
|
56.25
57.14
|
49 (6–96)
48 (6–84)
|
NA
NA
|
21 (12–36)
|
||
|
Vaezi et al. [15]
|
24 BoTx
24 PD
|
57 (44–69)
56 (37 –70)
|
41.47
29.17
|
NA
NA
|
11 (9–13)
10 (9–12)
|
2 (0–2.5)
3 (0–6)
|
NA
|
|
|
Annese et al. [16]
|
8 PD
8 BoTx
|
NA
|
NA
|
NA
NA
|
NA
|
NA
|
NA
|
|
|
Ghoshal et al. [17]
|
10 PD
7 BoTx
|
34.3 ± 9.0
42.4 ± 22.3
|
50
71.43
|
42.6 ± 49.2
107 ± 102
|
NA
NA
|
NA
NA
|
36.0 ± 12.8
34.3 ± 16.8
|
|
|
Mikaeli et al. [18]
|
20 BoTx
20 PD
|
59.8 ± 11.5a
50.1 ± 8.9
|
40
52.6
|
6.9 ± 6.2
5.9 ± 7.7
|
8.6 ± 2.2a
8.3 ± 2.2
|
2.2 ± 0.2
1.2 ± 0.2
|
12
|
|
|
Bansal et al. [19]
|
18 PD
16 BoTx
|
51.8 ± 3.4
49.8 ± 3.7
|
66.67
43.75
|
33.6 ± 10.2
23.4 ± 5.1
|
6.0 ± 0.5
5.8 ± 0.5
|
1.6 ± 0.7
1.9 ± 0.6
|
13 (3–23)
|
|
|
Mikaeli et al. [20]
|
27 PD
27 PD + BoTx
|
30 (24–45)
38 (26–49)
|
46.15
61.54
|
NA
NA
|
8 (6–10)
9 (6–10)
|
NA
|
12
|
|
|
Endoscopic myotomy: different treatment methods compared with laparoscopic myotomy
|
||||||||
|
Zaninotto et al. [21]
|
40 BoTx
40 LM
|
55 (19–73)
48 (18–71)
|
55
55
|
18 (2–240)
24 (2–240)
|
17 (8–22)
18 (6–22)
|
2.04
3.24
|
23 (12–34)
|
|
|
Zaninotto et al. [22]
|
20 LM
17 BoTx
|
47 (20–66)
40 (19–73)
|
60
64.71
|
24 (2–20)
26 (3–240)
|
17 (9–22)
17 (12–22)
|
NA
|
17 (12–34)
|
|
|
Suárez et al. [23]
|
14 LM
16 PD
|
39.5 (17–70)
43.2 (16–71)
|
42.76
37.5
|
17.5 (2–48)
22.7 (2–60)
|
12 (0–19)
8.5 (3–18)
|
NA
|
NA
|
|
|
Kostic et al. [24]
|
26 PD
25 LM
|
45 ± 18 (20–78)
43 ± 14 (17–66)
|
50
44
|
18 (2–120)
20 (8–106)
|
NA
|
NA
|
12
|
|
|
Patti et al. [25]
|
35 TM
133 LM + Dor
|
45 (11–96)
|
57.14
|
NA
|
NA
|
NA
|
28
23
|
|
|
Others
|
||||||||
|
Pasricha et al. [26]
|
11 BoTx
10 Placebo
|
57 (19–72)
54 (22–74)
|
45.45
60
|
36 (9–364)
47 (8–120)
|
7.1 ± 1.2a
5.9 ± 1.6
|
1.6 ± 2.2a
5.4 ± 2.0
|
9 (7–16)
|
|
|
Yi et al. [27]
|
21 FGBD
37 PD
|
39 (21–72)
22 (9–77)
|
47.62
51.35
|
NA
NA
|
NA
|
NA
|
NA
|
|
|
Mearin et al. [28]
|
17 PD
24 MD
|
52 (5)
50 (2)
|
52.94
66.67
|
49 (9)
48 (8)
|
NA
NA
|
NA
NA
|
12
|
|
|
Csendes et al. [29]
|
39 PD
40 EC
|
40.2 (16–73)
42.7 (15–80)
|
41.1
47.62
|
58 (24–144)
62 (26–156)
|
NA
NA
|
NA
NA
|
18 (24–44)
|
|
|
Richards et al. [30]
|
21 Heller
22 Heller + Dor
|
50 (24–76)
50 (22–73)
|
47.62
54.55
|
NA
NA
|
9 (5–10)
8 (5–10)
|
NA
|
||